ammonium hydroxide has been researched along with Fatty Liver, Nonalcoholic in 13 studies
azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Additionally, in patients with NAFLD, OTC enzyme concentration and activity were reduced and ammonia concentrations were increased, which was further exacerbated in those with NASH." | 5.48 | Urea cycle dysregulation in non-alcoholic fatty liver disease. ( Andreola, F; De Chiara, F; Felipo, V; Ferrandez, A; Gracia-Sancho, J; Grønbæk, H; Hamilton-Dutoit, S; Heebøll, S; Jalan, R; Marrone, G; Montoliu, C; Mookerjee, RP; Rombouts, K; Thomsen, KL; Vilstrup, H, 2018) |
| "We recently showed that the functional capacity for ureagenesis is deficient in non-alcoholic fatty liver disease (NAFLD) patients." | 3.91 | Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion. ( Eriksen, PL; Heebøll, S; Knop, FK; Rigbolt, K; Suppli, MP; Sørensen, M; Thomsen, KL; Veidal, SS; Vilstrup, H, 2019) |
| "Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in children and is associated with overweight and insulin resistance (IR)." | 1.72 | Alterations of Central Liver Metabolism of Pediatric Patients with Non-Alcoholic Fatty Liver Disease. ( Berndt, N; Bufler, P; Eckstein, J; Henning, S; Holzhütter, HG; Hudert, CA; Loddenkemper, C; Meierhofer, D; Sack, I; Wallach, I; Wiegand, S, 2022) |
| "In nonalcoholic fatty liver disease (NAFLD), fibrosis is the most important factor contributing to NAFLD-associated morbidity and mortality." | 1.56 | Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease. ( Andreola, F; Davies, N; De Chiara, F; Gracia-Sancho, J; Habtesion, A; Hall, A; Jalan, R; Jones, H; Leslie, J; Manicardi, N; Mann, J; Mookerjee, RP; Oakley, F; Paish, HL; Reed, LH; Rombouts, K; Thomsen, KL; Watson, AA, 2020) |
| "As the basis for NAFLD is excess calorie uptake and excess adipose tissue mass, the conservative therapeutic approach is weight loss by intense lifestyle change." | 1.51 | L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease. ( Canbay, A; Sowa, JP, 2019) |
| "The development of fibrosis is the most important factor contributing to NASH-associated morbidity and mortality." | 1.48 | Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis. ( Andreola, F; De Chiara, F; Jalan, R; Mookerjee, RP; Rombouts, K; Thomsen, KL; Vilstrup, H, 2018) |
| "Additionally, in patients with NAFLD, OTC enzyme concentration and activity were reduced and ammonia concentrations were increased, which was further exacerbated in those with NASH." | 1.48 | Urea cycle dysregulation in non-alcoholic fatty liver disease. ( Andreola, F; De Chiara, F; Felipo, V; Ferrandez, A; Gracia-Sancho, J; Grønbæk, H; Hamilton-Dutoit, S; Heebøll, S; Jalan, R; Marrone, G; Montoliu, C; Mookerjee, RP; Rombouts, K; Thomsen, KL; Vilstrup, H, 2018) |
| "We analyzed the presence of mild cognitive impairment (CI) by using the PHES battery of psychometric tests and measured the levels of ammonia and of the inflammatory cytokines IL-6 and IL-18 in blood of patients with different types of liver or dermatological diseases resulting in different grades of hyperammonemia and/or inflammation." | 1.38 | Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. ( Cassinello, N; Civera, M; Felipo, V; Garcia-Torres, ML; Jordá, E; Martinez-Valls, J; Molina, I; Montesinos, E; Montoliu, C; Olmo, JA; Ortega, J; Serra, MA; Urios, A; Wassel, A, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 5 (38.46) | 2.80 |
| Authors | Studies |
|---|---|
| Elfeki, MA | 1 |
| Singal, AK | 1 |
| Berndt, N | 1 |
| Hudert, CA | 1 |
| Eckstein, J | 1 |
| Loddenkemper, C | 1 |
| Henning, S | 1 |
| Bufler, P | 1 |
| Meierhofer, D | 1 |
| Sack, I | 1 |
| Wiegand, S | 1 |
| Wallach, I | 1 |
| Holzhütter, HG | 1 |
| Tranah, TH | 1 |
| Ballester, MP | 1 |
| Carbonell-Asins, JA | 1 |
| Jalan, R | 4 |
| Shawcross, DL | 1 |
| Delgado, TC | 2 |
| de Las Heras, J | 2 |
| Martínez-Chantar, ML | 2 |
| Gutiérrez-de-Juan, V | 1 |
| López de Davalillo, S | 1 |
| Fernández-Ramos, D | 1 |
| Barbier-Torres, L | 1 |
| Zubiete-Franco, I | 1 |
| Fernández-Tussy, P | 1 |
| Simon, J | 1 |
| Lopitz-Otsoa, F | 1 |
| Iruzubieta, P | 1 |
| Arias-Loste, MT | 1 |
| Villa, E | 1 |
| Crespo, J | 1 |
| Andrade, R | 1 |
| Lucena, MI | 1 |
| Varela-Rey, M | 1 |
| Lu, SC | 1 |
| Mato, JM | 1 |
| Thomsen, KL | 4 |
| De Chiara, F | 3 |
| Rombouts, K | 3 |
| Vilstrup, H | 3 |
| Andreola, F | 3 |
| Mookerjee, RP | 3 |
| Heebøll, S | 2 |
| Marrone, G | 1 |
| Montoliu, C | 2 |
| Hamilton-Dutoit, S | 1 |
| Ferrandez, A | 1 |
| Grønbæk, H | 1 |
| Felipo, V | 2 |
| Gracia-Sancho, J | 2 |
| Canbay, A | 1 |
| Sowa, JP | 1 |
| Habtesion, A | 1 |
| Jones, H | 1 |
| Davies, N | 1 |
| Manicardi, N | 1 |
| Hall, A | 1 |
| Paish, HL | 1 |
| Reed, LH | 1 |
| Watson, AA | 1 |
| Leslie, J | 1 |
| Oakley, F | 1 |
| Mann, J | 1 |
| Eriksen, PL | 1 |
| Rigbolt, K | 1 |
| Suppli, MP | 1 |
| Sørensen, M | 1 |
| Veidal, SS | 1 |
| Knop, FK | 1 |
| Lockman, KA | 1 |
| Htun, V | 1 |
| Sinha, R | 1 |
| Treskes, P | 1 |
| Nelson, LJ | 1 |
| Martin, SF | 1 |
| Rogers, SM | 1 |
| Le Bihan, T | 1 |
| Hayes, PC | 1 |
| Plevris, JN | 1 |
| Saleh, DO | 1 |
| Ahmed, RF | 1 |
| Amin, MM | 1 |
| Urios, A | 1 |
| Montesinos, E | 1 |
| Molina, I | 1 |
| Garcia-Torres, ML | 1 |
| Civera, M | 1 |
| Olmo, JA | 1 |
| Ortega, J | 1 |
| Martinez-Valls, J | 1 |
| Serra, MA | 1 |
| Cassinello, N | 1 |
| Wassel, A | 1 |
| Jordá, E | 1 |
1 review available for ammonium hydroxide and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Understanding gut-liver axis nitrogen metabolism in Fatty Liver Disease.
Topics: Ammonia; Glutaminase; Humans; Nitrogen; Non-alcoholic Fatty Liver Disease | 2022 |
12 other studies available for ammonium hydroxide and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Possible link between higher ammonia levels, non-alcoholic fatty liver-related cirrhosis and diabetes: Are we missing chronic kidney disease?
Topics: Ammonia; Diabetes Mellitus; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Renal Insuff | 2023 |
Alterations of Central Liver Metabolism of Pediatric Patients with Non-Alcoholic Fatty Liver Disease.
Topics: Ammonia; Carbohydrates; Child; Glutamine; Humans; Insulin Resistance; Lipids; Liver; Non-alcoholic F | 2022 |
Reply to: "Possible link between higher ammonia levels, non-alcoholic fatty liver-related cirrhosis and diabetes: Are we missing chronic kidney disease?"
Topics: Ammonia; Diabetes Mellitus; Humans; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease; Renal Insuff | 2023 |
A morphological method for ammonia detection in liver.
Topics: Adolescent; Adult; Aged; Ammonia; Animals; Child, Preschool; Cytological Techniques; Humans; Iodides | 2017 |
Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis.
Topics: Ammonia; Animals; Biopsy; Disease Models, Animal; Disease Progression; Fibrosis; Hepatic Stellate Ce | 2018 |
Urea cycle dysregulation in non-alcoholic fatty liver disease.
Topics: Adult; Aged; Ammonia; Animals; Carbamoyl-Phosphate Synthase (Ammonia); Cells, Cultured; DNA Methylat | 2018 |
L-Ornithine L-Aspartate (LOLA) as a Novel Approach for Therapy of Non-alcoholic Fatty Liver Disease.
Topics: Ammonia; Animals; Antioxidants; Dipeptides; Fatty Liver; Glutamine; Glutathione; Humans; Liver; Non- | 2019 |
Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease.
Topics: Ammonia; Animals; Cells, Cultured; Disease Models, Animal; Disease Progression; Female; Humans; Live | 2020 |
Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion.
Topics: Adult; Ammonia; Carbamoyl-Phosphate Synthase (Ammonia); Case-Control Studies; Female; Gene Expressio | 2019 |
Proteomic profiling of cellular steatosis with concomitant oxidative stress in vitro.
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Ammonia; Caprylates; Cell Line, Tumor; Cholesterol; Fatty | 2016 |
Modulatory role of Co-enzyme Q10 on methionine and choline deficient diet-induced non-alcoholic steatohepatitis (NASH) in albino rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Ammonia; Animals; Aspartate Aminotransferases; Bilirubin | 2017 |
Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy.
Topics: Adult; Aged; Ammonia; Cognitive Dysfunction; Fatty Liver; Female; Hepatic Encephalopathy; Humans; Hy | 2012 |